Sermorelin

Mechanism of action

Sermorelin is the synthetic 29-amino-acid N-terminal fragment of native human GHRH (the full-length molecule is 44 amino acids). The first 29 residues retain full GHRH-receptor agonism — the C-terminal extension of native GHRH 30-44 is not required for receptor binding or pituitary signalling. This makes sermorelin the prototype GHRH analogue and the foundation from which all modified GHRH-class compounds (CJC-1295, tesamorelin) have been derived. The molecular mechanism is identical to native GHRH: sermorelin binds the GHRH receptor (GHRHR, a class B G-protein-coupled receptor) on anterior-pituitary somatotrophs, activating Gαs/adenylate cyclase signalling. The downstream cAMP elevation triggers protein kinase A-mediated phosphorylation of CREB, driving transcription of the GH gene and pulsatile release of stored GH from secretory vesicles. Released GH binds the GH receptor on hepatocytes and peripheral tissues, activating JAK2/STAT5 signalling and driving IGF-1 production. The pharmacologically distinguishing feature of sermorelin is the unmodified amino-acid sequence and consequent short half-life. Native GHRH and sermorelin are both rapidly degraded by dipeptidyl peptidase-4 (DPP-4), which cleaves the N-terminal His-Ala bond (positions 1-2) to generate the inactive GHRH 3-29 fragment. This is the principal degradation pathway and gives sermorelin its ~5-12 minute plasma half-life — far shorter than the protease-resistant CJC-1295 (~30 minutes for the no-DAC variant, days for the DAC variant). The short half-life is mechanistically informative — it preserves the strictly pulsatile pattern of native GHRH-driven GH release, with each administration producing a discrete GH peak and rapid return to baseline. Somatostatin tone restores between pulses, maintaining the negative-feedback architecture that recombinant GH replacement disrupts. From a research-design perspective, sermorelin's pulsatile preservation is its principal pharmacological advantage. Studies that require physiological GH-axis modulation — including paediatric GH-deficiency diagnostic testing and adult GH-axis research where pulsatility must be preserved — favour sermorelin or short-acting analogues over sustained-release alternatives. The trade-off is dosing inconvenience: pulsatile protocols typically require multiple daily administrations or overnight subcutaneous infusion to reproduce the diurnal GH-release pattern. Combined administration with a GHRP-class secretagogue such as ipamorelin produces GH pulses materially larger than either monotherapy. The dual-pathway synergy — GHRH-receptor activation (Gαs/cAMP) plus GHSR ghrelin-receptor activation (Gq/PLC/calcium) plus somatostatin-tone suppression — is the foundation of the canonical 'sermorelin + ipamorelin' research protocol. This combination predates the CJC-1295 + ipamorelin protocol and remains the more physiologically conservative choice when pulsatility is the priority.

Sermorelin (GHRH 1-29) retains full GHRH-receptor agonism with the shortest plasma half-life (~5-12 minutes) of any GHRH-analogue compound — preserving the strictest pulsatile pattern of physiological GH release at the cost of multiple daily administrations. The compound's discontinuation as the Geref product in 2008 was driven by commercial dynamics (recombinant somatropin dominance) rather than safety or efficacy failure.

— Notable finding

Research history

Sermorelin acetate was developed in the 1970s and 1980s following the isolation and sequencing of native human GHRH by Roger Guillemin and colleagues at the Salk Institute in 1982 — work that ultimately won Guillemin the Nobel Prize for the broader characterisation of hypothalamic releasing hormones. The 1-29 fragment was identified as the minimal biologically active sequence retaining full GHRH-receptor agonism, and Serono (Switzerland) advanced the compound through clinical development under the product name Geref. Geref received FDA approval in 1990 for diagnostic evaluation of pituitary GH secretory function — primarily the differential diagnosis of paediatric growth-hormone deficiency. The approval indication was diagnostic rather than therapeutic; sermorelin's short half-life made chronic therapeutic dosing impractical relative to recombinant somatropin, which had become the standard of care for GH-deficiency replacement following its 1985 FDA approval. A modest paediatric therapeutic indication was added subsequently. Geref was marketed in the United States and several other markets through the 1990s and early 2000s. The product was discontinued by Serono in 2008 — not because of safety concerns or efficacy failure, but because of declining commercial demand against the better-supported recombinant somatropin alternatives and the broader commercial dynamics of GH-axis therapy. Following discontinuation, sermorelin's regulatory status reverted to unlicensed in most jurisdictions, with limited availability through compounding pharmacies in the United States as an off-label anti-ageing intervention. The compound entered the research-chemical market alongside CJC-1295 and ipamorelin in the late 2000s and early 2010s. Its sustained research-chemical-community use reflects its status as the prototype GHRH analogue, its favourable pulsatility profile, and the lower commercial cost relative to CJC-1295. The standard research-chemical-community protocol pairs sermorelin with ipamorelin for dual-pathway pulsatile GH release. With the discontinuation of Geref, sermorelin currently holds no marketing authorisation in any major jurisdiction, despite its earlier FDA approval and substantial clinical-trial history.

Reported research-model dose ranges

The ranges below are taken from published pre-clinical literature. They do not constitute a dosing recommendation for human use.

Summarised studies

Safety profile

Sermorelin has the largest published clinical-trial safety dataset of any GHRH-analogue compound, accumulated during the Geref clinical-development programme and post-marketing surveillance. The acute adverse-event profile is mild: injection-site reactions (erythema, transient pain, occasional itching) are the most common; mild transient flushing, headache, and brief warmth following injection are reported; occasional nausea and dysgeusia at higher doses; no clinically significant changes in routine haematology, biochemistry, or vital signs at therapeutic dose ranges. Anti-sermorelin antibodies have been reported with chronic dosing but did not produce clinically significant loss of efficacy in published trials. The chronic-dosing safety profile is correspondingly better-characterised than other GH-axis peptides. In paediatric GH-deficiency therapeutic use during the Geref era, multi-year dosing produced no signal of increased malignancy, no accelerated cardiovascular events, and no documented immune dysregulation. Insulin resistance with chronic dosing was noted but to a milder degree than chronic recombinant somatropin — reflecting the pulsatile-preserving release pattern. Diabetic retinopathy progression was monitored as a theoretical concern but did not emerge as a significant clinical issue. The theoretical concerns common to GH-axis peptides apply: chronic supraphysiological IGF-1 elevation theoretically carries oncogenic risk; insulin resistance with sustained GH/IGF-1 elevation is a recognised complication; diabetic retinopathy progression should be monitored in susceptible individuals. The pulsatile-pattern preservation of sermorelin protocols substantially mitigates the GH-receptor-desensitisation and IGF-1-receptor-downregulation concerns that affect chronic recombinant somatropin or sustained-release DAC-variant CJC-1295. Sermorelin's 29-amino-acid native sequence carries some immunogenicity risk; anti-drug antibodies with chronic dosing have been characterised in published work, but generally do not produce clinically significant loss of efficacy. The compound's natural-sequence identity also means cross-reactivity with native GHRH antibodies is theoretically possible, though not a documented clinical issue. No serious acute adverse events (anaphylaxis, severe hypotension, cardiac events) have been reported at research-protocol doses. The overall safety record is the most favourable of the GH-axis peptide class given the depth of clinical experience.

UK regulatory status

Sermorelin is not currently authorised as a medicinal product by the UK Medicines and Healthcare products Regulatory Agency (MHRA) following the global discontinuation of the Geref product in 2008. It holds no current marketing authorisation in any major jurisdiction. It is not a controlled substance under the Misuse of Drugs Act 1971. Sermorelin is captured by the World Anti-Doping Agency (WADA) Prohibited List under category S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) as a growth-hormone-releasing hormone analogue. Athletes subject to anti-doping testing should treat sermorelin and all GHRH-analogue compounds as prohibited both in-competition and out-of-competition regardless of claimed research purpose. MHRA enforcement actions concerning sermorelin supply specifically have not been published in the public domain. Generic warnings on unlicensed peptide supply for human use apply. Research-grade sermorelin for in-vitro and animal research is available from research-chemical suppliers; possession for bona fide laboratory research is generally unrestricted in the UK. Supply or administration to humans outside an authorised clinical-trial framework engages the Human Medicines Regulations 2012 and is generally an offence. The compound's historical FDA-approved status (Geref, 1990-2008) does not confer current UK marketing authorisation. For animal research under ASPA (Animals (Scientific Procedures) Act 1986), sermorelin work in vertebrates requires standard project and personal licences from the Home Office Drugs and Firearms Licensing Unit.

Frequently asked questions